Hologic to buy Gen-Probe for $3.7B

April 30, 2012 by MassDevice staff

Hologic agrees to pay $82.75 per share for molecular diagnostics firm Gen-Probe in a deal worth $3.7 billion.


Hologic (NSDQ:HOLX) agreed to pay about $3.7 billion for molecular diagnostics maker Gen-Probe (NSDQ:GPRO) in a cash-and-debt deal expected to close during the 2nd half of the year.

Hologic said it expects the deal to add 20¢ to its adjusted earnings per share in the first year following the deal's completion. The deal will drive about $75 million in cost savings as the companies integrate in the 3 years after the merger.

Sign up to get our free newsletters delivered straight to your inbox

"In addition, the combined company expects to have strong free cash flows, which will be used primarily to reduce debt with the expectation to return to pre-transaction leverage levels within 3 years," according to a press release.